GENFLOW BIOSCIENCES PLC Logo

GENFLOW BIOSCIENCES PLC

Developing gene therapies to target the aging process in humans and dogs.

GENF | IL

Overview

Corporate Details

ISIN(s):
GB00BP2C3V08
LEI:
213800HVOFXRXVEGDN62
Country:
United Kingdom
Address:
6 HEDDON STREET, W1B 4BT LONDON
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Genflow Biosciences PLC, founded in 2020, is a biotechnology company developing gene therapies to target the aging process in both humans and dogs. The company focuses on longevity science, aiming to extend healthspan and delay the onset of age-related diseases. Its lead compound, GF-1002, is a therapy based on delivering a centenarian variant of the SIRT6 gene, which has demonstrated promising preclinical results. Genflow's research and development pipeline also includes programs targeting specific age-related conditions such as sarcopenia (muscle loss).

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for GENFLOW BIOSCIENCES PLC and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-15 08:00
Regulatory News Service
Genflow Signs CDAs with Animal Health Companies
English 17.6 KB
2025-08-27 16:07
Major Shareholding Notification
Holding(s) in Company
English 21.7 KB
2025-08-18 08:00
Regulatory News Service
Company Update on Dog Trials
English 19.7 KB
2025-07-24 08:00
Earnings Release
Clinical Readiness Acceleration
English 17.7 KB
2025-07-17 08:00
Capital/Financing Update
Genflow Confirms Progression of Grant
English 18.0 KB
2025-06-12 11:16
Post-Annual General Meeting Information
Result of AGM
English 30.5 KB
2025-05-28 08:00
Regulatory News Service
Genflow Signs Master Services Agreement
English 13.4 KB
2025-05-15 08:00
Regulatory News Service
Key SIRT6 Patent Application
English 12.3 KB
2025-05-12 11:50
Major Shareholding Notification
Holding(s) in Company
English 68.7 KB
2025-05-07 19:07
Annual Report (ESEF)
Annual financial statements 2024
English 493.4 KB
2025-05-07 19:07
Annual Report
Annual financial statements 2024
English 1.5 MB
2025-03-28 08:10
Major Shareholding Notification
Holding in Company
English 23.0 KB
2025-03-28 08:00
Director's Dealing
Director Dealings
English 25.2 KB
2025-03-26 08:00
Share Issue/Capital Change
Institutional Investment
English 19.6 KB
2025-02-20 08:00
Regulatory News Service
Advancements in SIRT6 Variant Patent Application
English 19.4 KB

Automate Your Workflow. Get a real-time feed of all GENFLOW BIOSCIENCES PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for GENFLOW BIOSCIENCES PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Genmab Logo
Develops antibody therapeutics for cancer and serious diseases using proprietary technology.
Denmark GMAB
Genomic Vision Logo
Develops DNA analysis tools using Molecular Combing for genetic research and diagnostics.
France GV
genOway Logo
Develops genetically engineered preclinical models for biopharma and academic research.
France ALGEN
GenSight Biologics S.A. Logo
Biopharma developing gene therapies for retinal neurodegenerative diseases and CNS disorders.
France SIGHT
Genxone Spolka Akcyjna Logo
A biotech firm offering nanopore DNA/RNA sequencing services and medical diagnostics.
Poland GX1
Guard Therapeutics International AB Logo
Clinical-stage biotech developing protein-based therapies for acute kidney injury.
Sweden GUARD
Gubra A/S Logo
Preclinical CRO and peptide drug developer for metabolic and fibrotic diseases.
Denmark GUBRA
Hamlet BioPharma AB Logo
Developing selective therapies for cancer and infections like bladder cancer and UTIs.
Sweden HAMLET
HEMOGENYX PHARMACEUTICALS PLC Logo
Develops novel therapies for life-threatening blood disorders, cancers, and autoimmune diseases.
United Kingdom HEMO
Herantis Pharma Oyj Logo
Clinical-stage biotech developing therapies for neurodegenerative disorders like Parkinson's.
Finland HRTIS

Talk to a Data Expert

Have a question? We'll get back to you promptly.